Posted by SLS on October 5, 2010, at 16:04:51
In reply to Just the new we've been hoping to hear!, posted by ihatedrugs on October 5, 2010, at 15:37:00
> As it seems, we better get used to the crappy drugs we have now as it is not going to get any better for a while.
>
>
>
> http://www.medscape.com/viewarticle/721671Novartis purchased the rights to develop agomelatine (Valdoxan) in the US. I just hope that it doesn't turn out that Novartis, in effect, actually prevents the development of this drug by shelving CNS drug discovery projects. It could happen. Agomelatine seems to be novel in that it stimulates melatonin M1 and M2 receptors while selectively antagonizing serotonin 5-HT2c receptors. Clinical studies submitted to the EU have demonstrated efficacy. The drug has not yet been embraced by psychiatry in Europe. I don't know why.
- Scott
The measure of achievement lies not in how high the mountain,
but in how hard the climb.The measure of success lies only in how high one feels he must
climb to get there.
poster:SLS
thread:964804
URL: http://www.dr-bob.org/babble/20100926/msgs/964810.html